HPV Testing and Pap Test Market Size, Share & Trends Analysis Report By Test Type (HPV Testing, Pap Test), By Applications (Cervical Cancer Screening, Vaginal Cancer Screening), By Product (Instruments, Consumables, Services), By Technology (PCR, Immunodiagnostics, Other Technologies), By End-User (Hospitals and Clinics, Laboratories, Other End Users) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Hpv Testing and Pap Test Market Size

The global hpv testing and pap test market size was valued at USD 7.03 billion in 2025 and is projected to grow from USD 7.79 billion in 2026 to USD 17.77 billion by 2034, registering a CAGR of 10.85% during the forecast period from 2026 to 2034. North America dominated the hpv testing and pap test market with a market share of 38.6% in 2025.

Factors such as the High Incidence of Cervical Cancer in Middle-Aged Women and Technological Advancements, significantly drive the HPV testing and Pap test market demand by 2033.

The HPV and Pap test can aid in cervical cancer prevention and early detection. The HPV test examines for the virus (human papillomavirus) that can cause abnormalities in the cervix's cells. The Pap test, also called Pap smear, checks for pre-cancers, which are cervix-related cell abnormalities that, if left untreated, could progress into cervical cancer. The Pap test evaluates the appearance of the cells, while the HPV test only examines the virus.

Both tests can be carried out in a clinic or doctor's clinic office. The doctor will examine the vagina during the Pap test using a speculum, a plastic or metal device. This aids in examining the cervix and vagina and collecting a few cells and mucus from the cervix and its surrounding region the doctor. The cells are taken to a laboratory to undergo additional testing. The majority of women between the ages of 21 to 65 require Pap tests or Pap and HPV testing together.

Test Type Insights

The global market is divided into HPV and Pap tests. The Pap test segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 15.4% over the forecast period. Pap tests screen for abnormalities in normal or precancerous cells that may eventually turn into cervical cancer. The abnormality is generally caused by Human Papillomavirus (HPV). This test validates low-risk (minor) and high-risk (major) HPVs. The Pap test segment dominated the market due to the widespread implementation of screening programs.

Similarly, the cost-effective nature of these tests resulted in their higher penetration in low- and middle-income countries. According to the guidelines by the American Society of Obstetricians and Gynecologists in 2017, women should undergo a Pap test every two years after age 21. Therefore, such initiative factors are expected to fuel market growth during the forecast period.

Request Customizationto receive a tailored report.

Applications Insights

The global market is divided into cervical cancer screening and vaginal cancer screening. The cervical cancer screening segment dominates the global market and is predicted to exhibit a CAGR of 16.7% over the forecast period. The cervical cancer screening segment dominated the market because of the high incidence of cervical cancer and the increasing adoption of screening tests. These tests are used to detect abnormal cells in the cervical lining. Screening the cervix includes its cytology (Pap test) and screening for high-risk HPVs (HPV test). The latter has greater scope in cervical cancer screening, as most patients test positive for HPV.

Product Insights

The global market is bifurcated into instruments, consumables, and services. The consumables segment owns the largest market share and is anticipated to exhibit a CAGR of 16.2% over the forecast period. The consumables segment includes assays, kits, tests, reagents, collection devices, and accessories widely used in HPV and Pap testing. The huge share of the consumables segment is due to the repetitive use of these consumables in HPV and Pap testing procedures in hospitals, clinics, and diagnostic laboratories. Moreover, the increasing prevalence of HPV and cervical cancer and growing awareness about early diagnosis have significantly supported segment growth.

Technology Insights

The global market is segmented into PCR, immunodiagnostics, and others. The other technologies segment is the largest revenue contributor to the market and is projected to exhibit a CAGR of 15.7% over the forecast period. The other segment includes techniques such as colposcopy and cystoscopy. A colposcopy is performed when the Pap test results show abnormalities in the cervical cells. It is a diagnostic procedure that facilitates more detailed monitoring of the cervical region in case of abnormalities. On the other hand, a cystoscopy is done if the patient's biopsy shows the presence of cancer. It helps determine the spread of the cancer. Cystoscopy test comprises a slender tube attached to a lens and a light source inserted in the bladder through the urethra. This helps check the spread of cancer to the bladder and the urethra.

End-User Insights

The market for HPV testing and Pap test is bifurcated into hospitals and clinics, laboratories, and others. The hospitals and clinics segment owns the largest market share and is estimated to exhibit a CAGR of 15.5% over the forecast period. Hospitals and clinics are primary care settings for diagnosing and treating most medical conditions, including HPV infection and cervical cancer. Most of the population, in both developed and developing economies, relies on these facilities to diagnose, treat, and manage diseases. Hospitals and clinics are long-term care facilities that usually have patients who report specific symptoms and need further diagnosis. Prompt detection typically allows physicians to plan a proper patient treatment regimen in such settings. Favorable reimbursement policies have led to further segment growth, resulting in many HPV and Pap tests in hospital settings.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global HPV testing and Pap test market shareholder and is predicted to exhibit a CAGR of 15.8% during the forecast period. North America's dominant share can also be attributed to high awareness about early cervical cancer diagnosis, well-established screening guidelines, and favorable healthcare reimbursement. The North American market has expanded due to the high accessibility, adoption, and affordability of technologically advanced goods and services. Leading players' local presence and ongoing strategic initiatives have also significantly supported regional growth. For instance, in September 2020, BD filed a Premarket Approval Application (PMA) to the FDA to approve the ThinPrep Pap Test PreservCyt Solution vial and its Onclarity HPV Assay. The organization hopes to improve patient management through this PMA and increase the use of its Onclarity HPV Assay in the United States. In addition, in January 2019, Nurx, a U.S.-based telemedicine company, launched its Home HPV Screening test, enabling women to easily and conveniently identify their risk for cervical cancer from home.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Hpv Testing and Pap Test Market Trends

Europe is predicted to exhibit a CAGR of 15.3% over the forecast period. Europe held a significant market share, attributed to the high incidence of cervical cancer in key countries, including Germany, the UK, France, Italy, and Spain. As per the Globocan estimate for 2020, around 58,169 new cases of cervical cancer were diagnosed in the region, leading to around 25,989 deaths. In addition, a well-established healthcare system, cervical cancer screening guidelines, and favorable reimbursement policies in these key countries have aided further regional growth. Furthermore, easy access to advanced products due to the local presence of leading players has created a conducive environment for growth. For instance, Qiagen N.V. and F. Hoffmann-La Roche are leading Europe-based companies with strong supply chains in European countries. Ongoing initiatives undertaken by these major market players to curb the incidence of cervical cancer by improving diagnosis and screening are also expected to propel the market growth.

Asia Pacific Hpv Testing and Pap Test Market Trends

Asia-Pacific is predicted to exhibit an exponential CAGR over the forecast period. High rates of human papillomavirus (HPV) and cervical cancer in major economies like Japan, China, and India have contributed to this growth. It is expected that the region of Asia-Pacific will lead the way in technological innovation, accelerating market growth during the forecast period. For instance, Seegene, Inc. used a new AI-based assay development system in January 2018 to detect around eight DNA targets for each sexually transmitted infection and meningitis. Also expected to contribute to expansion over the forecast period are public-private sector efforts to enhance cervical cancer screening programs in this area.

In Latin America, the growth of the HPV and Pap testing market is associated with the surging incidence and mortality rate of cervical cancer in key countries like Brazil, Mexico, and Argentina. Globocan estimated that in 2020, around 41,734 new cases of cervix uterine cancer were diagnosed in the South American region, making it the 7th most common type of cancer in the region. The same source also stated that in 2020, around 22,221 people died of cervix uterine cancer in the South American region.

In the Middle East and Africa, the growth of the HPV and Pap testing market can be attributed to ongoing government initiatives to facilitate early diagnosis and treatment of cervical cancer in the Middle East and Africa region. For instance, in April 2020, the Government of Rwanda, with the support of two U.S. organizations, introduced a comprehensive nationwide cervical cancer prevention program in Kigali. This program facilitates modern molecular HPV diagnostic screening for women between 35 and 45. Similarly, the increased risk of developing cervical cancer due to lasting infection with certain types of HPV in countries such as South Africa is expected to create high demand for HPV and Pap testing products.

List of Key and Emerging Players in HPV Testing and Pap Test Market